FTC-133 Cells

FTC-133 is a human follicular thyroid carcinoma cell line derived from a lymph node metastasis. It is widely used to investigate the mechanisms underlying thyroid cancer progression, resistance to therapies, and gene expression changes associated with tumor biology. This cell line has been employed to study treatment responses in differentiated thyroid cancer (DTC) models, especially those linked to drug resistance and apoptosis pathways. Research involving FTC-133 has revealed its sensitivity to various inhibitors targeting DNA damage response pathways, such as the ATR inhibitor BAY 1895344, which can arrest growth, induce apoptosis, and enhance therapeutic outcomes when combined with tyrosine kinase inhibitors. FTC-133 cells have also been significant in understanding multidrug resistance mechanisms. For example, this cell line demonstrates resistance to doxorubicin, associated with the overexpression of P-glycoprotein (P-gp) and interactions with the CD47 receptor. These factors contribute to reduced drug uptake and diminished apoptosis through pathways involving the JNK signaling cascade. The modulation of these resistance mechanisms has been studied by inhibiting P-gp, which restores sensitivity to doxorubicin. Such findings underscore the role of FTC-133 in exploring targeted therapies and resistance pathways, informing the development of more effective treatment regimens for thyroid cancers.